A Phase Ib/II Study of Cisplatin, Paclitaxel, and RAD001 in Patients with Metastatic Breast Cancer (SPORE).
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 23 Aug 2016
At a glance
- Drugs Cisplatin (Primary) ; Everolimus (Primary) ; Paclitaxel (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms SPORE
- 07 Jun 2017 Biomarkers information updated
- 18 Jul 2016 Planned End Date changed from 1 Jan 2014 to 1 Jan 2017.
- 18 Jul 2016 Status changed from completed to active, no longer recruiting.